Background: Belantamab mafodotin (belamaf) is a first-in-class antibody-drug conjugate (ADC)
targeting B-cell maturation antigen (BCMA) that has shown clinically meaningful activity …

Purpose To develop a frailty index using the Rockwood Accumulation of Deficits approach
for the Medicare Health Outcomes Survey (MHOS) and apply it in a subset of older patients …

Autotransporters represent a large superfamily of known and putative virulence factors
produced by Gram-negative bacteria. They consist of an N-terminal “passenger domain” …

The incidence of multiple myeloma is increasing as the proportion of older adults is growing
rapidly. A critical evaluation of the evidence available is needed to guide the management …

Background Multiple myeloma is an incurable hematologic malignancy with significant recent
treatment advances; however, the magnitude of treatment burden among patients in the …

Background: Belantamab mafodotin (belamaf) is a first-in-class antibody-drug conjugate (ADC)
targeting B-cell maturation antigen (BCMA). Belamaf has shown clinically meaningful …

Introduction Multiple myeloma, a cancer of older adults, has seen significant improvement in
therapeutic options over the past two decades. Uncovering disparities in treatment patterns …

In their recent paper “A simplified frailty scale predicts outcomes in transplant-ineligible patients
with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial”[1], Facon et …

Multiple myeloma is the second most common hematological malignancy in the USA and
Europe. Despite improvements in the 5-year and overall survival rates over the past decade, …

Multiple myeloma is a disease of older adults, with a median age of 70 at diagnosis. Better
risk stratification strategies are required to identify older, fit adults who benefit from more …